AHA Conference 2024  — Semaglutide shows increased benefits in CKD patients based on their cardiovascular status and risk profile.

Dr Harriette Van Spall (McMaster University, CA) sits down with Dr Katherine Tuttle (University of Washington, US) to discuss the effects of semaglutide in patients with chronic kidney disease (CKD).

The FLOW trial (NCT03819153) is designed to assess the effect of semaglutide as compared to placebo in patients with chronic kidney disease and type 2 diabetes. 3533 patients were enrolled in the trial, and were randomized to receive either semaglutide or placebo. The primary outcome measure was the time to first occurrence of a composite primary outcome as defined by persistent eGFR decline of greater than or equal to 50% from trial start, reaching ESRD, death from kidney disease or death from cardiovascular disease.

Recorded remotely from Hamilton, CA and Seattle, WA, 2024.

Editors: Jordan Rance and Yazmin Sadik.
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David Ben-Harosh.

Support: This is an independent interview produced by Radcliffe CVRM.